Developmental Pipeline

Pipeline

Preclinical

Phase 1

Phase 2

Phase 3

COVID-19 with prior history of Cardiovascular Disease (CVD)

Oral Solution

more

close

COVID-19 with prior history of Cardiovascular Disease (CVD)

CardiolRx™

Cardiol has received approval from the U.S. Food and Drug Administration for its Investigational New Drug application to conduct a Phase II/III clinical trial investigating the efficacy and safety of CardiolRx in the treatment of hospitalized COVID-19 patients with a prior history of, or risk factors for, cardiovascular disease. Learn more…

Acute Myocarditis and other inflammatory heart disease

Oral Solution

more

close

Acute Myocarditis and other inflammatory heart disease

CardiolRx™

Cardiol has completed a Phase I safety and pharmacokinetic study of CardiolRx and is planning an international, multi-center Phase II study to investigate the therapeutic effects of CardiolRx on myocardial recovery in patients with acute myocarditis, the leading cause of sudden cardiac death in people under 35 years of age. Learn more…

Diastolic Heart Failure

Subcutaneous

more

close

Diastolic Heart Failure

CardiolRx™

The Company is also developing a subcutaneous formulation of CardiolRx to achieve higher bioavailability for the treatment of chronic heart failure.  Heart failure affects over six million people in North America and remains a leading cause of death and hospitalization with associated U.S. healthcare costs exceeding $30 billion annually. Learn more…